Loading
A live screen of the small-cap universe ordered by coverage-gap score — a composite of analyst count, last-coverage-change recency, and fundamental signal strength. Filter by cap, exchange, sector, and tier. Every row links to a source-backed profile.
State is in the URL. Share a filtered screen by copying the link.
| Ticker | Name · sector | Cap | ADV | Analysts | Tier | Gap , sorted ascending | Why surfaced |
|---|---|---|---|---|---|---|---|
| JXCZOTC | Westra Foods Consumer | $620M | $0.8M/d | 6 | covered | 41 | Capital structure unusually clean for the cohort; no current sell-side voice. |
| GRMCNYSE | Granite Mountain Copper Materials | $412M | $1.8M/d | 2 | low coverage | 60 | Permitted expansion finalized post last analyst update; LOM extension materially understated. |
| ATLSNYSE | Atlas Cement Holdings Materials | $612M | $2.1M/d | 2 | low coverage | 64 | Two-coverage cohort, regional infrastructure spend re-rates input prices not yet reflected. |
| TFYVNASDAQ | Vante Oil Energy | $439M | $0.6M/d | 1 | low coverage | 65 | Hedge-book mechanics flatter the FCF profile than consensus assumes for this cap bucket. |
| SGCPZNASDAQ | Ulmar Brands Consumer | $371M | $2.3M/d | 0 | no coverage | 80 | Capacity-utilization step-up not present in the prior analyst note's model. |
| NSKUNASDAQ | Zephir Materials Materials | $366M | $0.6M/d | 0 | no coverage | 80 | Capital structure unusually clean for the cohort; no current sell-side voice. |
| AZDCOTC | Halcyon Energy Utilities | $425M | $0.9M/d | 0 | no coverage | 81 | Capital structure unusually clean for the cohort; no current sell-side voice. |
| GQGVNYSE | Penna Bancshares Financials | $505M | $2.8M/d | 0 | no coverage | 83 | Customer-mix shift disclosed in the most recent annual; consensus has not refreshed. |
| USCSPNYSE | Orval Gas Utilities | $449M | $0.7M/d | 0 | no coverage | 83 | Sub-coverage cohort with backlog disclosure changing materially since the last analyst note. |
| SHXZNAMEX | Zephir Energy Energy | $508M | $0.4M/d | 0 | no coverage | 86 | Combined-ratio improvement on a tiny float; OTC listing keeps it off institutional desks. |